The HDAC inhibitor vorinostat reverses histone acetylation at these promoter regions and induces transcriptional derepression of the TGF-β pathway genes with a simultaneous growth-inhibition effect in ASXL1 mutants, indicating that HDAC inhibitors will be promising therapeutic drugs for MDS and AML with ASXL1 and SETBP1 mutations (224). This evidence concerns the gene ASXL1 and myelodysplastic syndrome.